AstraZeneca Shrugs Off COVID Antibody’s Inferiority In Therapy Setting, Sees Prevention As Main Role
Injection Cut Risk By 50%
AstraZeneca’s anti-SARS-CoV-2 antibody product is unlikely to rival Regeneron or Vir/GSK’s offerings in mild-to-moderate patients, where Merck’s newly-submitted oral molnupiravir will also change treatment.
You may also be interested in...
Merck’s antiviral could play a big role, but only if it proves effective in broader settings, such as post-exposure prophylaxis.
AZD7442 can provide antibodies in people who cannot generate their own after vaccination but could in theory also be used to protect other groups, including unvaccinated populations.
As rival Phase III gene therapy trials get underway, Sarepta’s product could have the edge in safety and efficacy over its rival from Pfizer, but the chance of failure remains high.